Searches for “sermorelin GHK” and “sermorelin glycine” can make these combinations sound like standard versions of the same medicine. They are not interchangeable names. GHK is a peptide, glycine is an amino acid, and a product labeled GHK-Cu contains a copper-associated form of GHK.
The first question is what the actual prescription contains and how it is intended to be used. A sublingual combination, an injectable blend, and a topical cosmetic product require different evidence and handling. Do not assume that a study about one applies to the others.
Read the full ingredient list and route. Evidence for one ingredient does not establish the safety or benefit of a combined tablet or injection.
Decode the label before judging the promise
Swipe sideways to read the full table. You can also select the table and use the arrow keys.
| Ingredient name | What to clarify |
|---|---|
| Sermorelin | Exact amount, route, and intended treatment goal |
| GHK | Whether the label means GHK alone or another form |
| GHK-Cu | Whether the copper-associated ingredient is present and by which route |
| Glycine | Its amount and role in this preparation |
| Citrulline | Whether it is an additional active ingredient and why it is included |
The names matter because the benefits and risks cannot be inferred from the word “blend.” Ask for the full pharmacy label before assuming two programs provide the same product. If an advertisement and the prescription use different terms, the pharmacist should resolve the difference.
What Everlife currently describes
Everlife's GHK product page describes a sublingual mint tablet combining sermorelin, GHK, and citrulline. Its catalog lists this as a separate product from plain sermorelin. That is evidence of the marketed formulation, not independent verification of the promotional outcome claims.
The Everlife review compares the separate offers. A review of plain sermorelin should not silently endorse the GHK combination or treat both products as having the same research base.
Three ingredients do not automatically mean three proven benefits
Each ingredient can have a plausible biological role while the combined product still lacks strong clinical evidence for its advertised use. To demonstrate a useful combination effect, a study would need to evaluate the actual formula, route, dose, and outcomes in a relevant population.
Claims that a blend is synergistic, improves skin and muscle together, or works better than another treatment need direct support. Adding the conclusions of unrelated studies is not a clinical trial of the combination.
The Endocrine Society aging statement provides context for the limits of hormone-based healthy-aging claims. The tablet guide addresses the additional question of whether an oral or sublingual formulation has evidence for absorption and outcomes.
Route-specific safety concerns should stay route-specific
The FDA's page on bulk substances with potential safety risks discusses concerns for injectable GHK-Cu, including immunogenicity and limited human safety data. That warning should not be relabeled as proof about every topical or oral GHK product. It also should not be ignored when someone proposes an injectable copper-peptide blend.
Similarly, the absence of a particular formulation from that page is not FDA approval. The FDA explains the broader limits of compounded-drug review. Ask the clinician and pharmacist to address each component and the proposed route rather than relying on a general quality badge.
What about sermorelin and glycine?
Glycine can appear in a formulation for a stated pharmacy or treatment purpose. Its presence does not establish improved sermorelin absorption, better sleep, or greater muscle gain. Those claims require supporting evidence for that preparation.
Ask whether it is being used as an active component or for another formulation role, and whether it changes storage or administration. A familiar nutrient name is not a reason to assume an injectable preparation is equivalent to a dietary supplement.
Keep one accountable treatment plan
Do not add separate ingredients to a prescribed vial or combine products in one syringe. The peptide-stack guide explains why compatibility, exposure, and monitoring become harder to assess when several agents are involved.
Before choosing a combination, ask what measurable benefit it is expected to add over the simpler option, what additional uncertainty it introduces, and how you would identify which ingredient caused a reaction. A clear answer is more useful than a larger ingredient count.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 20, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.